Cagrilintide Cost in the US

If you searched “cagrilintide cost,” you almost certainly expected a number — a monthly figure, a per-vial price, maybe a comparison table. The honest answer is that there isn’t one, and understanding why there isn’t one is far more useful than any figure a website might invent. In 2026, cagrilintide has no legitimate US price because it is not an approved medicine, it is not sold on its own, and it cannot lawfully be compounded. Everything below explains what that means in practice and what you’d really be buying if you ignore it.

Why there is no legitimate price

Cost only exists where there is a lawful product to buy. For cagrilintide, that product doesn’t exist in the US yet.

Cagrilintide is a long-acting amylin analogue — an injectable that works alongside the gut hormone pathway GLP-1 drugs target. It is still investigational: it has been studied in Novo Nordisk’s Phase 3 REDEFINE (obesity) and REIMAGINE (type 2 diabetes) programs, but it has never been approved by the FDA for any use, on its own or otherwise.

Crucially, cagrilintide has not even been filed as a standalone product. The only regulatory submission is for CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. Novo Nordisk submitted that New Drug Application to the FDA in December 2025, with a decision expected in late 2026. That timing matters for the cost question: a drug with no approval and no launch has no list price, no pharmacy markup, no insurance contract, and no manufacturer cash-pay program. There is simply nothing to price.

Note: “No price” is the accurate state of the world here, not a gap in this page. A medicine that hasn’t launched cannot have a real cost, and anyone presenting one is presenting a guess or a gray-market figure.

The “cagrilintide for sale” trap

So why do search results show cagrilintide vials with dollar figures attached? Because a separate, unregulated market exists — and its prices are exactly the problem this page is warning about.

Those listings come from research-chemical suppliers that sell peptides labeled “for research use only” (RUO). That label is doing a lot of work. It means the product is not sold as a medicine, is not made to pharmaceutical standards, and is not intended for human use. A low number next to it is not a discount on a drug; it is the price of an unverified substance.

For an unapproved injectable, that distinction is not academic. A research vial has:

• Unknown actual content. The label says one thing; independent testing of gray-market peptides routinely finds under-dosing, over-dosing, the wrong compound, or contaminants. You cannot price-shop a product when you don’t know what’s in it.
• No prescriber. Nobody has evaluated whether the compound is appropriate for you, what it might interact with, or what to monitor.
• No pharmacy or oversight. There is no licensed dispenser standing behind the vial and no recourse if something is wrong.
• No lawful patient route. RUO is not a loophole for self-treatment; it’s a category that explicitly isn’t for patients.

The cheaper the vial, the louder these alarms should ring. A “bargain” on an unapproved injectable of unknown purity is not a saving — it’s a transfer of risk onto you.

Why compounding isn’t a cheaper backdoor either

With some peptides, compounding pharmacies have historically offered a lower-cost route. That is not available for cagrilintide, and this is one of the clearest distinctions on the whole site.

The FDA has stated that cagrilintide cannot be used in compounding pharmacies under federal law. There is no patient-specific 503A pathway and no 503B outsourcing route for it. So a clinic, med-spa, or telehealth site advertising “compounded cagrilintide” — at any price — is operating outside the legal framework, not offering a budget version of an approved drug. The price is irrelevant when the route itself isn’t lawful.

This is different from the situation with the GLP-1 molecules during their shortage period, and different again from peptides moving through the FDA’s separate Category review process. For a clear picture of where compounded GLP-1 products actually stand now, see our compounded GLP-1 legal status explainer; the short version for cagrilintide is that none of those routes apply to it.

What CagriSema might cost — and why any number now is a guess

It’s reasonable to ask what you’ll eventually pay once the combination is approved. The honest answer is that no one can tell you yet.

CagriSema hasn’t launched, so it has no published list price, no formulary placement, and no savings program. Pricing for branded obesity medicines is set by the manufacturer at launch and then heavily shaped by insurance, cash-pay programs, and direct-to-consumer channels. For context, established branded GLP-1 obesity drugs have carried list prices in the four-figures-per-month range before discounts, with most patients paying far less through coverage or manufacturer programs — but that is context, not a forecast for CagriSema. Until there’s a launch and a label, treat every CagriSema price you see as speculation.

A few things will shape the eventual number:

• Whether it lands as a premium “next-generation” drug. Novo has positioned CagriSema on its weight-loss efficacy, which can support premium pricing.
• Competition. It would enter a market with several established options, which can pull pricing and rebates in the patient’s favor over time.
• Coverage decisions. As with current GLP-1s, insurance and Medicare rules will matter more to your out-of-pocket cost than the headline list price. Our GLP-1 insurance coverage explainer walks through how that logic works for the drugs already on the market.

What you can actually price today

If the practical goal behind your search is “I want this kind of result and I want to know what it costs,” there are lawful, priced answers — they just aren’t cagrilintide.

The semaglutide half of CagriSema is already an approved, available medicine. So is tirzepatide. These are the products with real, knowable costs right now:

• Semaglutide under the brands Wegovy (weight management) and Ozempic (type 2 diabetes) has published list prices, manufacturer cash-pay options, and insurance pathways. Our semaglutide cost page breaks down what people actually pay across routes.
• Tirzepatide (Zepbound, Mounjaro) is the other approved dual-mechanism family with comparable, knowable pricing.
• For another investigational comparison point, retatrutide cost covers a different unapproved drug in the same situation — no list price, no lawful route — so you can see this isn’t unique to cagrilintide.

In other words: the thing you can buy today is the approved GLP-1, not the investigational amylin analogue. If your interest is specifically the cagrilintide-plus-semaglutide combination, the only lawful path is to wait for CagriSema’s approval — not to assemble a version of it from gray-market parts.

Red flags when a site quotes you a price

Because the legitimate answer is “no price yet,” any concrete cagrilintide price is itself a warning sign. Treat these as reasons to walk away:

• A standalone “cagrilintide” product at any price. It isn’t approved or sold as a medicine; the listing is RUO or unlawful.
• “Compounded cagrilintide” from a clinic or pharmacy. The FDA has said this isn’t lawful; a price tag doesn’t change that.
• “Pre-order CagriSema now” with a fixed monthly cost. The drug hasn’t launched and has no price; this is a sales hook, not a quote.
• No prescriber, no evaluation, just a cart. “Buy and inject” with no medical assessment is the core warning sign for every gray-market peptide.
• Pressure framing — “limited supply,” “before it gets restricted,” “research stock.” Legitimate medicines aren’t sold this way.

The bottom line

The reason you can’t find a clean cagrilintide price is the same reason you shouldn’t trust the prices you do find: the product isn’t an approved, lawfully sold medicine in the US in 2026. It exists today only as an investigational ingredient inside a combination product that has been filed with the FDA but not yet approved. Until CagriSema launches, the only honest cost figures belong to the approved GLP-1 drugs already on pharmacy shelves — and those are where a real cost comparison should start.

This reflects the US regulatory and market situation as of June 2026 and will change as the FDA completes its CagriSema review. For what cagrilintide is and how access might work later, see what is cagrilintide and how to get cagrilintide in the US.